NeucaLTS:0MJR 98 EBITDA Margin % is 3.84% as of Mar. 2026, which is 32% above its 10-year median of 2.92. GuruFocus rates LTS:0MJR with a GF Score™ of 98/100 and a GF Value™ of zł938.86. The stock has 4 warning signs investors should review. Among 119 Medical Distribution companies, Neuca ranks worse than 64.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neuca's EBITDA for the
three
months ended in Mar. 2026 was zł136 Mil. Neuca's Revenue for the
three
months ended in Mar. 2026 was zł3,557 Mil. Therefore, Neuca's EBITDA margin for the quarter that ended in Mar. 2026 was 3.84%.
Neuca (LTS:0MJR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neuca EBITDA Margin % Related Terms
Neuca EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neuca's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0MJR vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Neuca's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuca EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Neuca's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neuca's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuca (LTS:0MJR) has a EBITDA Margin % of 3.84% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuca and its competitors. This is 32% above median its historical median of 2.92. Over the past decade, Neuca's EBITDA Margin % has ranged from 2.22 to 3.38. According to the industry distribution chart, Neuca ranks #77 out of 119 companies in the Medical Distribution industry, placing it in the top 64.7%.
Is Neuca's EBITDA Margin % too high?
Neuca's current EBITDA Margin % of 3.84% is 32% above median its 10-year median of 2.92. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 3.38. The Medical Distribution industry median EBITDA Margin % is 4.31. Neuca's value of 3.84% is 10.9% below this industry median. Based on the distribution chart, Neuca ranks #77 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Neuca has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Neuca's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Neuca ranks #77 out of 119 companies for EBITDA Margin %. This places Neuca in the lower half of its industry. The industry median EBITDA Margin % is 4.31. Neuca's value of 3.84% is 10.9% below this benchmark. Historically, Neuca's own EBITDA Margin % has ranged from 2.22 to 3.38 over the past decade. While the company's 10-year median is 2.92 vs. the industry median of 4.31, Neuca has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuca's current EBITDA Margin % of 3.84% is 10.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neuca and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuca's current EBITDA Margin % is 3.84%, which is 32% above median its own 10-year median of 2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuca stock overvalued right now?
Neuca (LTS:0MJR) has a current EBITDA Margin % of 3.84%. The stock's GF Value™ is zł938.86, compared to a current price of zł760.00 — trading 19.1% below its estimated fair value. The current EBITDA Margin % is 3.84%, which is 32% above median its 10-year median of 2.92 and 10.9% below the Medical Distribution industry median of 4.31. Neuca's overall GF Score™ is 98/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neuca (LTS:0MJR), the current EBITDA Margin % is 3.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuca (LTS:0MJR) Overvalued in 2026?
Based on GuruFocus' analysis, Neuca stock appears to be undervalued.
The current stock price of zł760.00 is trading 19.1% below its estimated GF Value™ of zł938.86.
Key valuation signals for LTS:0MJR:
EBITDA Margin %: 3.84% (32% above median its 10-year median of 2.92)
GF Value™: zł938.86 vs. price of zł760.00 (19.1% below fair value)
Industry Position: 10.9% below the Medical Distribution median (#77 of 119)
No single metric tells the full story. See the LTS:0MJR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuca SA is a wholesale distributor of pharmaceuticals in Poland. The company's segment includes Pharmacy wholesale; Manufacture of pharmaceuticals; Outpatient medical care clinics; Clinical trials and Insurance activities. It generates maximum revenue from the Pharmacy wholesale segment.
98GF Score
Get the complete analysis for LTS:0MJR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0MJR has been successfully added to your 
